The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

The following is a summary of “Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

New treatment options are revolutionizing ways to manage and reduce the effects of food allergy. Biologics - medications that ...

Dr. Daniel Jobe, the medical mirector at UNC Campus Health, said that Campus Health had over 100 student visits for allergies ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

A new study looked at a medicine called omalizumab, usually used for asthma, to see if it could help these kids. Researchers found that this drug helped many children eat foods they were allergic to.

Food allergies are on the rise. For kids with less severe peanut allergies, one potential treatment could be found in the ...

In this video, Raj Chovatiya, MD, PhD, discussed continued updates in the use of topical ruxolitinib in pediatric patients with atopic dermatitis.

The following is a summary of “Patient and physician perspectives on disease burden in chronic spontaneous urticaria,” published in the March 2025 issue of Annals of Allergy, Asthma & Immunology by ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

Pollen season is getting longer and more intense, but these steps can keep you comfortableThe first line of defense against ...